Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.

A 8-week, Multi Center(10),Single Arm, Open-labeled Prospective Study of Valsartan 160 mg in 200 Mild to Moderate Chinese Hypertension Patients Forced Titrated From 2-week Therapy of Valsartan 80 mg.

To evaluate efficacy and safety of valsartan 160mg in Chinese hypertensive patients.

Inclusion Criteria:

• Naive primary hypertension patients or primary hypertensive patients on mono antihypertensive therapy:
• All treatment-naive patients need to have 140mmHg≤MSSBP<180mmHg and 90mmHg≤MSDBP< 110mmHg at visit 1
• For patients on mono antihypertensive therapy, MSSBP/MSDBP should <160/100mmHg at visit 1 (the beginning of screening period); and at visit 2(the beginning of theraputic period), they should have MSSBP≥140 mmHg and <180mmHg AND MSDBP≥90 mmHg and <110mmHg

Exclusion Criteria:

• Severe hypertension
• Malignant hypertension
• Secondary hypertension
• Renal dysfunction(serum creatinine > 2.0mg(176.8μmol/L)at visit 1)
• Hepatic disease
• History of hypertensive encephalopathy or cerebrovascular accident within 6 months
• History of myocardial infarction, coronary revascularization within 6 months
• Type 1 diabetes mellitus
• patietns with HbA1c >8% at visit 1
• Women in pregnancy and lactation
• Potentially fertile female patients not using effective contraceptive methods
• Be allergy to study drug.

Other protocol defined inclusion/exlusion criteria may apply